Cue secures $481M from DOD for COVID-19 tests

By LabPulse.com staff writers

October 15, 2020 -- Cue Health has received $481 million from the U.S. Department of Defense (DOD) to produce and distribute 6 million point-of-care COVID-19 tests by March 2021.

The funding is awarded by the DOD on behalf of the U.S. Department of Health and Human Services (HHS). Cue will manufacture the tests at its facilities in San Diego.

The test, called Cue COVID-19, runs on the company's Cue Health Monitoring System and received emergency use authorization from the U.S. Food and Drug Administration in June 2020. It is a molecular test that uses a nasal swab to detect SARS-CoV-2 RNA and delivers results in about 20 minutes, according to the firm.

HHS: FDA review not needed for coronavirus LDTs
Laboratory-developed tests (LDTs) to diagnose whether patients are infected with the SARS-CoV-2 virus will not have to undergo review by the U.S. Food...
Cue gets FDA clearance for point-of-care coronavirus test
Cue Health has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for its rapid, portable, point-of-care test for the...
Department of Defense orders mobile medical labs for rapid COVID-19 testing
The U.S. Department of Defense has ordered three mobile medical labs for rapid COVID-19 diagnostic testing from MRIGlobal, a Kansas City-based nonprofit...
HHS to let pharmacists give COVID-19 tests
Pharmacists will be allowed to order and administer diagnostic tests for COVID-19 under a new guidance issued April 8 by the U.S. Department of Health...
Abbott, DOD advance research on concussion blood test
Abbott, the U.S. Department of Defense (DOD), and an academic research network plan to conduct a clinical trial to study Abbott's point-of-care blood...

Copyright © 2020 LabPulse.com

Last Updated ls 10/15/2020 12:50:31 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email